The Cigna Group Announces President & COO Brian Evanko to Succeed David M. Cordani as Chief Executive Officer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 03 2026
0mins
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CI
Wall Street analysts forecast CI stock price to rise
16 Analyst Rating
14 Buy
2 Hold
0 Sell
Strong Buy
Current: 284.330
Low
300.00
Averages
335.63
High
378.00
Current: 284.330
Low
300.00
Averages
335.63
High
378.00
About CI
The Cigna Group is a global health company. The Company has two segments: Evernorth Health Services and Cigna Healthcare. Evernorth Health Services includes its Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the healthcare system to work better and help people live richer, healthier lives. Cigna Healthcare includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to customers and clients. Its Other Operations include corporate-owned life insurance (COLI), the Company's run-off operations and other non-strategic businesses. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help the clients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cost Analysis of Direct-to-Consumer Pharmacies for Generic Drugs
- Cost Savings on Medications: An analysis by the University of Texas MD Anderson Cancer Center reveals that consumers using Mark Cuban Cost Plus Drug pay less out-of-pocket for approximately 80% of prescriptions when their cost-sharing exceeds $15, leading to significant savings.
- Impact of High Cost-Sharing: For consumers with drug plan benefits that require more than $100 in cost-sharing, the median out-of-pocket cost is $25 with Cost Plus Drug compared to $140 with insurance, highlighting the clear advantages of direct-to-consumer pharmacies.
- Data-Driven Insights: The findings are based on an examination of over 60 million generic prescription claims from a national commercial claims database, ensuring the reliability and broad applicability of the results, which emphasize potential savings for consumers when choosing their medication payment methods.
- Consumer Recommendations: Researchers advise that consumers should consider direct-to-consumer pharmacies if their out-of-pocket costs exceed $15, optimizing their medication expenses and enhancing economic efficiency.
See More
US Stocks Close Higher: S&P 500 Hits All-Time High
- Market Performance: The S&P 500 rose by 0.61% and the Nasdaq 100 increased by 1.76%, reaching all-time highs, indicating strong demand for tech stocks amid falling oil prices and progress in US-Iran peace talks.
- Oil Price Volatility: WTI crude oil prices fell to a 2.5-week low as US-Iran negotiations aimed at reopening the Strait of Hormuz progressed, although military actions by US Central Command pressured market sentiment, leading to declines in energy stocks.
- Economic Data Impact: The Chicago Fed National Activity Index rose to a 13-month high of 0.14, surpassing expectations, while a slight decline in the consumer confidence index reflects the complexities of economic recovery, potentially influencing future market trends.
- Earnings Reports: As of Tuesday, 83% of the 475 S&P 500 companies reported earnings above expectations, with Q1 earnings projected to grow by 12% year-on-year, although excluding the tech sector, the increase is only 3%, highlighting disparities across industries.
See More
US Stock Indices Rally, Led by Technology Stocks
- Strong Market Performance: The S&P 500 Index rose by 0.81% and the Nasdaq 100 Index increased by 1.74%, reaching all-time highs, indicating robust market support for technology stocks, particularly amid falling crude oil prices and declining bond yields.
- Mixed Economic Data: The Chicago Fed National Activity Index rose to a 13-month high of 0.14, surpassing expectations, while the S&P Composite-20 home price index increased by only 0.83% year-on-year, below the expected 0.90%, suggesting weakness in the housing market that could impact future consumer confidence.
- Volatile Oil Market: WTI crude oil prices fell to a 2.5-week low due to progress in US-Iran peace talks, although US Central Command's strikes on Iranian targets caused market fluctuations, highlighting the ongoing geopolitical influence on energy markets.
- Earnings Season Insights: So far, 83% of the 475 S&P 500 companies have beaten earnings estimates, with Q1 earnings projected to rise by 12% year-on-year; however, excluding the technology sector, the increase is only 3%, reflecting pressure on overall economic growth.
See More
US Stocks Rally as Oil Prices Drop Amid Iran Talks
- Strong Market Performance: The S&P 500 index rose by 0.72% and the Nasdaq 100 by 1.42%, reaching all-time highs, reflecting market confidence in economic recovery, particularly against the backdrop of falling oil prices and declining bond yields.
- Oil Price Volatility: WTI crude oil prices fell to a 2.5-week low, dropping over 3% today, primarily influenced by progress in US-Iran peace talks, although military actions by US Central Command have added pressure to market sentiment.
- Mixed Economic Data: The Chicago Fed National Activity Index rose to a 13-month high of 0.14, exceeding expectations, while the S&P Composite-20 home price index increased by only 0.83% y/y, below the expected 0.90%, indicating weakness in the housing market.
- Earnings Reports: So far, 83% of the 475 S&P 500 companies have beaten earnings estimates, with Q1 earnings projected to rise by 12% y/y, but excluding the tech sector, the increase is only 3%, the lowest in two years, highlighting disparities across industries.
See More
Barclays Downgrades Cigna to Equal-Weight Amid Limited Upside
- Rating Downgrade Impact: Barclays downgraded Cigna from overweight to equal-weight, indicating limited upside potential for the stock, reflecting a cautious market outlook on its future performance.
- Price Target Analysis: Barclays set a price target of $304 for Cigna, which translates to approximately 6% upside based on the May 22 close, highlighting investor concerns regarding its profitability.
- Uncertain Earnings Outlook: Analyst Andrew Mok noted that while the prospects for health insurance margin recovery are underway, Cigna has limited embedded earnings and multiple upside potential, particularly given its low government exposure.
- Transition Uncertainty: The lack of clarity regarding Cigna's pharmacy benefits manager model transition, coupled with concerns over easing investment spending, may negatively impact its future financial performance.
See More
Cigna Group Rated Among Top Dividend Growth Stocks
- Dividend Growth Potential: With a 5-year dividend growth rate of 42.40%, Cigna Group is recognized as one of the 10 Best Dividend Growth Stocks to Buy and Hold for 3 Years, showcasing its strong performance and appeal in dividend returns.
- Analyst Rating Upgrade: UBS raised its price target on Cigna Group from $375 to $400 while reiterating a Buy rating, indicating analysts' confidence in the company's guidance increase following stronger-than-expected Q1 results from managed care organizations.
- Market Trends Support: Analysts noted that improved Medicare Advantage rates, steadier ACA exchange enrollment, and modest Medicaid outperformance have bolstered confidence in margin recovery, despite ongoing cost pressures related to specialty drugs and behavioral health expenses.
- Management Outlook: Morgan Stanley increased Cigna's price target from $355 to $361, maintaining an Overweight rating, as management meetings highlighted the underappreciated specialty opportunity, with the upcoming September investor day expected to further showcase this long-term strategy.
See More
Cost Analysis of Direct-to-Consumer Pharmacies for Generic Drugs
- Cost Savings on Medications: An analysis by the University of Texas MD Anderson Cancer Center reveals that consumers using Mark Cuban Cost Plus Drug pay less out-of-pocket for approximately 80% of prescriptions when their cost-sharing exceeds $15, leading to significant savings.
- Impact of High Cost-Sharing: For consumers with drug plan benefits that require more than $100 in cost-sharing, the median out-of-pocket cost is $25 with Cost Plus Drug compared to $140 with insurance, highlighting the clear advantages of direct-to-consumer pharmacies.
- Data-Driven Insights: The findings are based on an examination of over 60 million generic prescription claims from a national commercial claims database, ensuring the reliability and broad applicability of the results, which emphasize potential savings for consumers when choosing their medication payment methods.
- Consumer Recommendations: Researchers advise that consumers should consider direct-to-consumer pharmacies if their out-of-pocket costs exceed $15, optimizing their medication expenses and enhancing economic efficiency.
See More
US Stocks Close Higher: S&P 500 Hits All-Time High
- Market Performance: The S&P 500 rose by 0.61% and the Nasdaq 100 increased by 1.76%, reaching all-time highs, indicating strong demand for tech stocks amid falling oil prices and progress in US-Iran peace talks.
- Oil Price Volatility: WTI crude oil prices fell to a 2.5-week low as US-Iran negotiations aimed at reopening the Strait of Hormuz progressed, although military actions by US Central Command pressured market sentiment, leading to declines in energy stocks.
- Economic Data Impact: The Chicago Fed National Activity Index rose to a 13-month high of 0.14, surpassing expectations, while a slight decline in the consumer confidence index reflects the complexities of economic recovery, potentially influencing future market trends.
- Earnings Reports: As of Tuesday, 83% of the 475 S&P 500 companies reported earnings above expectations, with Q1 earnings projected to grow by 12% year-on-year, although excluding the tech sector, the increase is only 3%, highlighting disparities across industries.
See More
US Stock Indices Rally, Led by Technology Stocks
- Strong Market Performance: The S&P 500 Index rose by 0.81% and the Nasdaq 100 Index increased by 1.74%, reaching all-time highs, indicating robust market support for technology stocks, particularly amid falling crude oil prices and declining bond yields.
- Mixed Economic Data: The Chicago Fed National Activity Index rose to a 13-month high of 0.14, surpassing expectations, while the S&P Composite-20 home price index increased by only 0.83% year-on-year, below the expected 0.90%, suggesting weakness in the housing market that could impact future consumer confidence.
- Volatile Oil Market: WTI crude oil prices fell to a 2.5-week low due to progress in US-Iran peace talks, although US Central Command's strikes on Iranian targets caused market fluctuations, highlighting the ongoing geopolitical influence on energy markets.
- Earnings Season Insights: So far, 83% of the 475 S&P 500 companies have beaten earnings estimates, with Q1 earnings projected to rise by 12% year-on-year; however, excluding the technology sector, the increase is only 3%, reflecting pressure on overall economic growth.
See More
US Stocks Rally as Oil Prices Drop Amid Iran Talks
- Strong Market Performance: The S&P 500 index rose by 0.72% and the Nasdaq 100 by 1.42%, reaching all-time highs, reflecting market confidence in economic recovery, particularly against the backdrop of falling oil prices and declining bond yields.
- Oil Price Volatility: WTI crude oil prices fell to a 2.5-week low, dropping over 3% today, primarily influenced by progress in US-Iran peace talks, although military actions by US Central Command have added pressure to market sentiment.
- Mixed Economic Data: The Chicago Fed National Activity Index rose to a 13-month high of 0.14, exceeding expectations, while the S&P Composite-20 home price index increased by only 0.83% y/y, below the expected 0.90%, indicating weakness in the housing market.
- Earnings Reports: So far, 83% of the 475 S&P 500 companies have beaten earnings estimates, with Q1 earnings projected to rise by 12% y/y, but excluding the tech sector, the increase is only 3%, the lowest in two years, highlighting disparities across industries.
See More
Barclays Downgrades Cigna to Equal-Weight Amid Limited Upside
- Rating Downgrade Impact: Barclays downgraded Cigna from overweight to equal-weight, indicating limited upside potential for the stock, reflecting a cautious market outlook on its future performance.
- Price Target Analysis: Barclays set a price target of $304 for Cigna, which translates to approximately 6% upside based on the May 22 close, highlighting investor concerns regarding its profitability.
- Uncertain Earnings Outlook: Analyst Andrew Mok noted that while the prospects for health insurance margin recovery are underway, Cigna has limited embedded earnings and multiple upside potential, particularly given its low government exposure.
- Transition Uncertainty: The lack of clarity regarding Cigna's pharmacy benefits manager model transition, coupled with concerns over easing investment spending, may negatively impact its future financial performance.
See More
Cigna Group Rated Among Top Dividend Growth Stocks
- Dividend Growth Potential: With a 5-year dividend growth rate of 42.40%, Cigna Group is recognized as one of the 10 Best Dividend Growth Stocks to Buy and Hold for 3 Years, showcasing its strong performance and appeal in dividend returns.
- Analyst Rating Upgrade: UBS raised its price target on Cigna Group from $375 to $400 while reiterating a Buy rating, indicating analysts' confidence in the company's guidance increase following stronger-than-expected Q1 results from managed care organizations.
- Market Trends Support: Analysts noted that improved Medicare Advantage rates, steadier ACA exchange enrollment, and modest Medicaid outperformance have bolstered confidence in margin recovery, despite ongoing cost pressures related to specialty drugs and behavioral health expenses.
- Management Outlook: Morgan Stanley increased Cigna's price target from $355 to $361, maintaining an Overweight rating, as management meetings highlighted the underappreciated specialty opportunity, with the upcoming September investor day expected to further showcase this long-term strategy.
See More
